Novanta (NOVT) Stock Overview
Provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NOVT from our risk checks.
NOVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Novanta Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$131.52 |
| 52 Week High | US$187.12 |
| 52 Week Low | US$98.76 |
| Beta | 1.46 |
| 1 Month Change | 3.22% |
| 3 Month Change | 11.61% |
| 1 Year Change | -18.64% |
| 3 Year Change | 9.98% |
| 5 Year Change | 25.77% |
| Change since IPO | 725.22% |
Recent News & Updates
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Jun 16
Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
May 20Recent updates
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Jun 16Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
May 20Here's Why Novanta (NASDAQ:NOVT) Can Manage Its Debt Responsibly
May 03Should You Think About Buying Novanta Inc. (NASDAQ:NOVT) Now?
Apr 19Novanta: A Trusted Yet Premium Technology Partner
Apr 06Novanta Inc.'s (NASDAQ:NOVT) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors
Apr 05There May Be Some Bright Spots In Novanta's (NASDAQ:NOVT) Earnings
Mar 05Novanta (NASDAQ:NOVT) Has Some Way To Go To Become A Multi-Bagger
Feb 09Is Novanta (NASDAQ:NOVT) A Risky Investment?
Jan 24Should You Investigate Novanta Inc. (NASDAQ:NOVT) At US$151?
Jan 07Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Jan 01Novanta Inc.'s (NASDAQ:NOVT) Business Is Yet to Catch Up With Its Share Price
Dec 21Novanta (NASDAQ:NOVT) May Have Issues Allocating Its Capital
Oct 15What You Can Learn From Novanta Inc.'s (NASDAQ:NOVT) P/S
Sep 12Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Sep 02
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Is It Too Late To Consider Buying Novanta Inc. (NASDAQ:NOVT)?
Aug 24Novanta Inc.'s (NASDAQ:NOVT) Intrinsic Value Is Potentially 21% Below Its Share Price
Aug 02Novanta (NASDAQ:NOVT) Might Be Having Difficulty Using Its Capital Effectively
Jun 22Does Novanta (NASDAQ:NOVT) Have A Healthy Balance Sheet?
May 30Investors Still Waiting For A Pull Back In Novanta Inc. (NASDAQ:NOVT)
May 08Novanta (NASDAQ:NOVT) Has Some Way To Go To Become A Multi-Bagger
Feb 24Does Novanta (NASDAQ:NOVT) Have A Healthy Balance Sheet?
Feb 05Getting In Cheap On Novanta Inc. (NASDAQ:NOVT) Is Unlikely
Dec 29Why Novanta Inc. (NASDAQ:NOVT) Could Be Worth Watching
Nov 20Here's Why We Think Novanta (NASDAQ:NOVT) Is Well Worth Watching
Nov 01Does This Valuation Of Novanta Inc. (NASDAQ:NOVT) Imply Investors Are Overpaying?
Oct 19Novanta (NASDAQ:NOVT) Seems To Use Debt Quite Sensibly
Sep 21Return Trends At Novanta (NASDAQ:NOVT) Aren't Appealing
Sep 06What Does Novanta Inc.'s (NASDAQ:NOVT) Share Price Indicate?
Aug 19Here's Why We Think Novanta (NASDAQ:NOVT) Is Well Worth Watching
Jul 16Slowing Rates Of Return At Novanta (NASDAQ:NOVT) Leave Little Room For Excitement
Jun 06These 4 Measures Indicate That Novanta (NASDAQ:NOVT) Is Using Debt Reasonably Well
May 16Should You Investigate Novanta Inc. (NASDAQ:NOVT) At US$156?
Apr 13Here's Why We Think Novanta (NASDAQ:NOVT) Is Well Worth Watching
Mar 29Investors Met With Slowing Returns on Capital At Novanta (NASDAQ:NOVT)
Feb 27These 4 Measures Indicate That Novanta (NASDAQ:NOVT) Is Using Debt Safely
Feb 12Is Novanta Inc. (NASDAQ:NOVT) Potentially Undervalued?
Jan 12We Ran A Stock Scan For Earnings Growth And Novanta (NASDAQ:NOVT) Passed With Ease
Dec 28Shareholder Returns
| NOVT | US Electronic | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.3% | 0.4% |
| 1Y | -18.6% | 24.0% | 12.6% |
Return vs Industry: NOVT underperformed the US Electronic industry which returned 23.1% over the past year.
Return vs Market: NOVT underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 6.3% |
| Electronic Industry Average Movement | 8.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: NOVT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NOVT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles.
Novanta Inc. Fundamentals Summary
| NOVT fundamental statistics | |
|---|---|
| Market cap | US$4.63b |
| Earnings (TTM) | US$70.62m |
| Revenue (TTM) | US$951.70m |
Is NOVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVT income statement (TTM) | |
|---|---|
| Revenue | US$951.70m |
| Cost of Revenue | US$523.44m |
| Gross Profit | US$428.26m |
| Other Expenses | US$357.64m |
| Earnings | US$70.62m |
Last Reported Earnings
Mar 28, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.96 |
| Gross Margin | 45.00% |
| Net Profit Margin | 7.42% |
| Debt/Equity Ratio | 50.7% |
How did NOVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/08 15:26 |
| End of Day Share Price | 2025/07/08 00:00 |
| Earnings | 2025/03/28 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novanta Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Mason | Baird |
| Ishan Majumdar | Baptista Research |
| Andrew Buscaglia | Berenberg |